Democratic Senators to Discuss Novo Nordisk’s Withdrawal of Levemir

Democratic Senators are set to meet with Novo Nordisk to discuss the withdrawal of long-acting insulin Levemir. The decision to discontinue Levemir has raised concerns, prompting lawmakers to seek clarification from the pharmaceutical company. Despite facing scrutiny, Novo Nordisk maintains that the move was not influenced by the success of its other products. The upcoming meeting reflects ongoing efforts to address pharmaceutical pricing and access to essential medications.